SCHEMBL7835591

SCHEMBL7835591

CCOc1cccc2c(C)cccc12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 3/20 0.54
CYP1A2 P05177 2/20 0.54
L3MBTL1 Q9Y468 4/20 0.46
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
ALDH1A1 P00352 4/20 0.45
LMNA P02545 4/20 0.43
HPGD P15428 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
MAPT P10636 6/20 0.42
KDM4E B2RXH2 2/20 0.42
PABPC1 P11940 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
GRK6 P43250 1/20 0.42
GAA P10253 2/20 0.41
POLB P06746 1/20 0.41
RECQL P46063 1/20 0.41
ADORA2B P29275 1/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30503999 0.89 ALDH1A1 (0.54) CYP2A6CYP1A2L3MBTL1MEN1KMT2A
SCHEMBL3818341 0.89 ALDH1A1 (0.54) CYP2A6CYP1A2L3MBTL1MEN1KMT2A
SCHEMBL8229480 0.88 CYP1A2 (0.54) CYP2A6CYP1A2L3MBTL1MEN1KMT2A
SCHEMBL7836740 0.82 HTR1B (0.50) CYP2A6CYP1A2L3MBTL1TDP1GAA
SCHEMBL19612325 0.81 CYP2A6 (0.45) CYP2A6L3MBTL1MEN1KMT2AALDH1A1
SCHEMBL15772901 0.81 SYK (0.47) CYP2A6ALDH1A1LMNAHPGDSMN1; SMN2
SCHEMBL18417214 0.80 MAPT (0.47) CYP2A6CYP1A2L3MBTL1MEN1KMT2A
SCHEMBL12454829 0.80 CYP1A2 (0.50) CYP2A6CYP1A2MEN1KMT2AALDH1A1
SCHEMBL29378631 0.80 ALDH1A1 (0.54) L3MBTL1MEN1KMT2AALDH1A1LMNA
SCHEMBL50817 0.80 ALDH1A1 (0.54) L3MBTL1MEN1KMT2AALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0676398-B1 Heterocyclic compounds having anti-diabetic activity, their preparation and their use SANKYO CO (JP) 2001-10-24 EP disclosed
US-6117893-A Heterocyclic compounds having anti-diabetic activity and their use SANKYO COMPANY, LIMITED (JP) 2000-09-12 US disclosed
EP-1022274-A1 Oxazolidinedione and Thiazolidinedione derivatves, their preparation and their use Sankyo Company Limited (JP) 2000-07-26 EP disclosed
US-5977365-A HYPOGLYCEMIC AGENTS SANKYO COMPANY, LIMITED (JP) 1999-11-02 US disclosed
US-5962470-A Heterocyclic compounds having anti-diabetic activity and their use SANKYO COMPANY, LIMITED (JP) 1999-10-05 US disclosed
US-5886014-A TREATMENT AND/OR PROPHYLAXIS OF A VARIETY OF DISORDERS, INCLUDING HYPERLIPEMIA, HYPERGLYCEMIA, OBESITY, IMPAIRED GLUCOSE TOLERANCE (IGT), INSULIN RESISTANCE AND DIABETIC COMPLICATIONS SANKYO COMPANY, LIMITED (JP) 1999-03-23 US disclosed
US-5834501-A TREATING DIABETES OR HYPERLIPEMIA SANKYO COMPANY, LIMITED (JP) 1998-11-10 US disclosed
US-5739345-A HYPOGLYCEMIC AND ANTIDIABETIC AGENTS SANKYO COMPANY, LIMITED (JP) 1998-04-14 US disclosed
US-5624935-A ANTIDIABETIC AGENTS, HYPOGLYCEMIC AGENTS OR ANTILIPEMIC AGENTS SANKYO COMPANY, LIMITED 1997-04-29 US disclosed
EP-0745600-A1 Benzimidazole derivatives, their preparation and their therapeutic use SANKYO COMPANY LIMITED (JP) 1996-12-04 EP disclosed
EP-0676398-A2 Heterocyclic compounds having anti-diabetic activity, their preparation and their use SANKYO COMPANY LIMITED (JP) 1995-10-11 EP disclosed